Patents by Inventor Kelly J. McClure
Kelly J. McClure has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11957898Abstract: The present invention consists of an implantable device with at least one package that houses electronics that receives input data or signals, and optionally, power, from an external system through at least one coil attached to the at least one package, processes the input data and delivers electrical pulses to neural tissue through at least one array of multiple electrodes that is/are attached to the at least one package. The invention, or components thereof, is/are intended to be installed in the head, or on or in the cranium, or on the dura, or on or in the brain.Type: GrantFiled: July 30, 2018Date of Patent: April 16, 2024Assignee: Second Sight Medical Products, Inc.Inventors: Robert J Greenberg, Brian V Mech, Kelly H McClure
-
Patent number: 11897900Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: December 18, 2020Date of Patent: February 13, 2024Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20230339900Abstract: A compound of Formula (I) or Formula (II), pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with casein kinase 1 delta (CSNK1D) modulation, such as those associated with mood/psychiatric disorders, neurodegenerative diseases, cancers, addiction and substance abuse disorders, pain, and metabolic diseases. Wherein R1, R2, R3, R4, R1a, R2a, R3, and R4a are defined herein.Type: ApplicationFiled: September 16, 2021Publication date: October 26, 2023Inventors: Terry Patrick Lebold, Stefan McCarver, Kelly J. McClure, Cathy Preville, Mark Seierstad, Brock T. Shireman, Jocelyn Wang, Dongpei Wu, Wei Zhang, Jeannie M. Ziff
-
Publication number: 20220315604Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: December 18, 2020Publication date: October 6, 2022Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 11427601Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 30, 2021Date of Patent: August 30, 2022Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 10947252Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: GrantFiled: August 19, 2019Date of Patent: March 16, 2021Assignee: Janssen Pharmaceutica NVInventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Publication number: 20200055874Abstract: Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.Type: ApplicationFiled: August 19, 2019Publication date: February 20, 2020Inventors: J. Kent Barbay, Wenying Chai, Gavin C. Hirst, Kevin D. Kreutter, David A. Kummer, Kelly J. McClure, Rachel T. Nishimura, Amy Y. Shih, Jennifer D. Venable, Hariharan Venkatesan, Jianmei Wei
-
Patent number: 10047101Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: August 2, 2017Date of Patent: August 14, 2018Assignee: Janssen Pharmaceautica NVInventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
-
Patent number: 9926333Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: May 22, 2015Date of Patent: March 27, 2018Assignee: JANSSEN PHARMACEUTICA NVInventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
-
Patent number: 9884878Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: June 2, 2015Date of Patent: February 6, 2018Assignee: JANSSEN PHARMACEUTICA NVInventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
-
Publication number: 20170327514Abstract: The present invention relates to compounds of Formula (I), or a form thereof wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: ApplicationFiled: August 2, 2017Publication date: November 16, 2017Inventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
-
Patent number: 9745328Abstract: The present invention relates to compounds of Formula (I), or a form thereof wherein ring A1, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: January 31, 2014Date of Patent: August 29, 2017Assignee: Janssen Pharmaceutica NVInventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
-
Patent number: 9738649Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.Type: GrantFiled: July 12, 2016Date of Patent: August 22, 2017Assignee: JANSSEN PHARMACEUTICA N.V.Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
-
Patent number: 9732093Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: January 31, 2014Date of Patent: August 15, 2017Assignee: JANSSEN PHARMACEUTICA NVInventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
-
Publication number: 20160318942Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.Type: ApplicationFiled: July 12, 2016Publication date: November 3, 2016Inventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
-
Patent number: 9422293Abstract: Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.Type: GrantFiled: January 17, 2014Date of Patent: August 23, 2016Assignee: Janssen Pharmaceutica NVInventors: Brett D. Allison, Bryan James Branstetter, J. Guy Breitenbucher, Michael D. Hack, Natalie A. Hawryluk, Alec D. Lebsack, Kelly J. McClure, Jeffrey E. Merit
-
Publication number: 20150376212Abstract: The present invention relates to compounds of Formula (I), or a form thereof wherein ring A1, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: ApplicationFiled: January 31, 2014Publication date: December 31, 2015Inventors: GENESIS M. BACANI, WENDY ECCLES, ANNE E. FITZGERALD, STEVEN D. GOLDBERG, MICHAEL D. HACK, NATALIE A. HAWRYLUK, WILLIAM M. JONES, JOHN M. KEITH, PAUL KRAWCZUK, ALEC D. LEBSACK, ALICE LEE-DUTRA, JING LIU, KELLY J. MCCLURE, STEVEN P. MEDUNA, DANIEL J. PIPPEL, MARK D. ROSEN, ZACHARY S. SALES
-
Publication number: 20150259357Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I).Type: ApplicationFiled: June 2, 2015Publication date: September 17, 2015Inventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales
-
Publication number: 20150252008Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, L and R2 are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: ApplicationFiled: May 22, 2015Publication date: September 10, 2015Inventors: Wendy Eccles, Anne E. Fitzgerald, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Jing Liu, Neelakandha S. Mani, Kelly J. McClure, Steven P. Meduna, Mark D. Rosen
-
Patent number: 9079866Abstract: The present invention relates to compounds of Formula (I), or a form thereof, wherein ring A, R1, R2, R3, R3?, L, W, and V are as defined herein, useful as FLAP modulators. The invention also relates to pharmaceutical compositions comprising compounds of Formula (I). Methods of making and using the compounds of Formula (I) are also within the scope of the invention.Type: GrantFiled: January 31, 2014Date of Patent: July 14, 2015Assignee: JANSSEN PHARMACEUTICA NVInventors: Genesis M. Bacani, Wendy Eccles, Anne E. Fitzgerald, Steven D. Goldberg, Michael D. Hack, Natalie A. Hawryluk, William M. Jones, John M. Keith, Paul Krawczuk, Alec D. Lebsack, Alice Lee-Dutra, Jing Liu, Kelly J. McClure, Steven P. Meduna, Daniel J. Pippel, Mark D. Rosen, Zachary S. Sales